Celanese
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Celanese's revenues will wither -5.7% and EPS will grow 10.3%.
The average estimate for revenue is $1.52 billion. On the bottom line, the average EPS estimate is $0.64.
Revenue details
Last quarter, Celanese booked revenue of $1.61 billion. GAAP reported sales were 11% lower than the prior-year quarter's $1.81 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $0.93. GAAP EPS of $0.73 for Q3 were 30% lower than the prior-year quarter's $1.05 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 20.1%, 210 basis points worse than the prior-year quarter. Operating margin was 10.4%, 180 basis points worse than the prior-year quarter. Net margin was 7.3%, 190 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $6.44 billion. The average EPS estimate is $3.77.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 350 members out of 379 rating the stock outperform, and 29 members rating it underperform. Among 96 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 92 give Celanese a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Celanese is outperform, with an average price target of $50.49.
The rich are different than you and me: They might not notice the moneymaking stories right under our noses. In our new report, "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice," we give you three Peter Lynch-inspired buy-what-you-know stocks for the 99%. Click here for instant access to this free report.
- Add Celanese to My Watchlist.